<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528241</url>
  </required_header>
  <id_info>
    <org_study_id>CABP688A2102</org_study_id>
    <nct_id>NCT01528241</nct_id>
  </id_info>
  <brief_title>Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)</brief_title>
  <official_title>A Multi-center, Open-label Study in Elderly Healthy Volunteers and Elderly Patients With Major Depressive Disorder to Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to characterize the regional distribution of [11C] ABP688 in brain by&#xD;
      positron emission tomography (PET).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binding of [11C] ABP688 to mGlu5 receptors</measure>
    <time_frame>Day 1</time_frame>
    <description>Binding of [11C]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood levels of [11C] ABP688</measure>
    <time_frame>Day 1, up to 60 minutes</time_frame>
    <description>Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of [11C] ABP688. Specific times are recorded at the clinical site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in [11C]ABP688 binding to mGlu5 receptors</measure>
    <time_frame>Day 1</time_frame>
    <description>Using data generated as described above, data will be analyzed to determine if there are difference in binding between healthy volunteers and patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>ABP688</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly MDD patients and demography matched healthy volunteer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP688</intervention_name>
    <description>Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.</description>
    <arm_group_label>ABP688</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects 55-80 (inclusive)&#xD;
&#xD;
          -  Subjects in good health&#xD;
&#xD;
        At screening:&#xD;
&#xD;
          -  oral body temperature between 35-37.5C&#xD;
&#xD;
          -  systolic blood pressure: 90-140 mm Hg&#xD;
&#xD;
          -  diastolic blood pressure: 50-90 mm Hg&#xD;
&#xD;
          -  pulse rate: 40-90 bpm&#xD;
&#xD;
          -  Female subjects of child bearing potential must have been using a double-barrier local&#xD;
             contraception&#xD;
&#xD;
          -  Postmenopausal women must have had no menstrual bleeding&#xD;
&#xD;
          -  Subjects must have weighed at least 50 kg&#xD;
&#xD;
          -  All subjects must provide informed consent&#xD;
&#xD;
          -  All subjects must have been able to communicate well with investigator&#xD;
&#xD;
        Specific to Major depression disorder (MDD)&#xD;
&#xD;
        Patients had to show following level of symptomatology:&#xD;
&#xD;
          -  HAM-D (17-item scale) &gt; 16&#xD;
&#xD;
          -  CGI &gt; 4 (moderately ill)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Specific criteria for healthy volunteers:&#xD;
&#xD;
        - Presence and/or history of clinically significant major neurological or psychiatric&#xD;
        disorder&#xD;
&#xD;
        Specific criteria for MDD patients:&#xD;
&#xD;
          -  Presence and/or history of a clinically significant major neurological or psychiatric&#xD;
             disorder other than MDD or generalized anxiety disorder&#xD;
&#xD;
          -  Axis I co-morbidity was excluded except anxiety spectrum disorders&#xD;
&#xD;
        Criteria for both:&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Subjects with history of or symptoms/complaints consistent with mild cognitive&#xD;
             impairment&#xD;
&#xD;
          -  Use of any psychotropic prescription drugs&#xD;
&#xD;
          -  Coffee consumers more than 6 cups/day&#xD;
&#xD;
          -  Participation in any clinical investigation&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood&#xD;
&#xD;
          -  Significant illness within 2 weeks prior to dosing&#xD;
&#xD;
          -  A known hypersensitivity to study drug&#xD;
&#xD;
          -  MRI scan that showed evidence of stroke&#xD;
&#xD;
          -  Any surgical or medical condition which might have significantly altered distribution&#xD;
&#xD;
          -  Clinical evidence of any abnormal lab value&#xD;
&#xD;
          -  History of immunodeficiency disease&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen&#xD;
&#xD;
          -  Presence of contraindications to PET scan investigations- Presence of&#xD;
             contraindications to MRI investigations&#xD;
&#xD;
          -  Evidence from an Allen test of incomplete communication&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Current use of anticonvulsant&#xD;
&#xD;
          -  Significant radiation exposure&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=5125</url>
    <description>Results for CABP688A2102 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABP688</keyword>
  <keyword>Tracer</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

